Medically reviewed by Jamin Brahmbhatt, MD The treatment of metastatic castration-resistant prostate cancer (mCRPC) involves ...

Pluvicto, a prostate cancer drug, has gained expanded approval that triples the number of patients with metastatic disease ...

The phase 2a LEGION-100 trial seeks to evaluate the safety and effectiveness of the SYNC-T/SV-102 combination therapy for treating metastatic castration-resistant prostate cancer (mCRPC) and to ...

This is the first trial to prospectively demonstrate the impact of bone-protecting agents use on fracture risk for men receiving an androgen receptor pathway inhibitor.

“[MCRPC is] like a car that keeps moving, even though you’re pushing on the brakes in the form of hormone therapy.” It’s common for hormone therapy, known as androgen deprivation therapy ...

Overall survival and progression-free survival outcomes appear similar for lutetium-177 and actinium-225 in select patients with mCRPC, with some differences between radioligand therapies.

The sector has seen billions in merger and acquisition activity in recent years; a September 2024 analysis by Insight ...

The FDA approved several therapies in oncology in the month of March 2025. These drugs included treatments for gastrointestinal and genitourinary cancers such as prostate-specific membrane antigen ...

Men with metastatic castration-resistant prostate cancer (mCRPC) lived 19-20 months whether they received docetaxel plus pembrolizumab (Keytruda) or placebo. The addition of pembrolizumab did not ...

Metastatic castration-resistant prostate cancer causes urinary symptoms, fatigue, pain, and more. This article covers the ...

Androgen deprivation is the mainstay of advanced prostate cancer treatment. Despite initial responses, almost all patients progress to castration-resistant prostate cancer (CRPC). The ...